Search

Your search keyword '"Pryser, E."' showing total 10 results
Start Over Author "Pryser, E."
10 results on '"Pryser, E."'

4. Evaluation and Validation of Artificial Intelligence (AI) Delineation Models for CBCT-guided Stereotactic Online Adaptive Radiotherapy (STAR) Targeting Upper Abdominal Malignancies

Author

Cai, B., primary, Laugeman, E., additional, Hao, Y., additional, Kim, T., additional, Pryser, E., additional, Jiang, Z., additional, Green, O.L., additional, Price, A., additional, Kim, H., additional, Robinson, C.G., additional, Mutic, S., additional, Hugo, G.D., additional, and Henke, L.E., additional

Published
2020
Full Text
View/download PDF

10. Simulated computed tomography-guided stereotactic adaptive radiotherapy (CT-STAR) for the treatment of locally advanced pancreatic cancer.

Author

Schiff JP, Price AT, Stowe HB, Laugeman E, Chin RI, Hatscher C, Pryser E, Cai B, Hugo GD, Kim H, Badiyan SN, Robinson CG, and Henke LE

Subjects
Humans, Organs at Risk, Prospective Studies, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted methods, Tomography, X-Ray Computed, Neoplasms, Second Primary, Pancreatic Neoplasms diagnostic imaging, Pancreatic Neoplasms radiotherapy, Pancreatic Neoplasms surgery, Radiosurgery methods, Radiotherapy, Image-Guided methods, Radiotherapy, Intensity-Modulated methods
Abstract

Background and Purpose: We conducted a prospective, in silico imaging clinical trial to evaluate the feasibility and potential dosimetric benefits of computed tomography-guided stereotactic adaptive radiotherapy (CT-STAR) for the treatment of locally advanced pancreatic cancer (LAPC)., Materials and Methods: Eight patients with LAPC received five additional CBCTs on the ETHOS system before or after their standard of care radiotherapy treatment. Initial plans were created based on their initial simulation anatomy (P I ) and emulated adaptive plans were created based on their anatomy-of-the-day (P A ). The prescription was 50 Gy/5 fractions. Plans were created under a strict isotoxicity approach, in which organ-at-risk (OAR) constraints were prioritized over planning target volume coverage. The P I was evaluated on the patient's anatomy-of-the-day, compared to the daily P A, and the superior plan was selected. Feasibility was defined as successful completion of the workflow in compliance with strict OAR constraints in ≥80% of fractions., Results: CT-STAR was feasible in silico for LAPC and improved OAR and/or target dosimetry in 100% of fractions. Use of the P I based on the patient's anatomy-of-the-day would have yielded a total of 94 OAR constraint violations and ≥1 hard constraint violation in 40/40 fractions. In contrast, 39/40 P A met all OAR constraints. In one fraction, the P A minimally exceeded the large bowel constraint, although dosimetrically improved compared to the P I . Total workflow time per fraction was 36.28 minutes (27.57-55.86)., Conclusion: CT-STAR for the treatment of LAPC cancer proved feasible and was dosimetrically superior to non-adapted CT-stereotactic body radiotherapy., (Copyright © 2022 Elsevier B.V. All rights reserved.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results